Novel Therapeutic Approach to Improve Hematopoiesis By Targeting Myeloid Derived Suppressor Cells with a Humanized Anti-CD33 Antibody

被引：0
|
作者：
Eksioglu, Erika A. [1 ]
Heider, Karl-Heinz [2 ]
Rueter, Bjoern [3 ]
Burnette, Alexis [4 ]
Wei, Max [4 ]
McGraw, Kathy [4 ]
Basiorka, Ashley A. [4 ,5 ]
Patel, Parthik [4 ]
Lancet, Jeffrey [4 ]
Komrokji, Rami [4 ]
List, Alan F. [4 ]
Wei, Sheng [4 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Boehringer Ingelheim RCV, Vienna, Austria
[3] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[5] Univ S Florida, Canc Biol PhD Program, Tampa, FL USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate
    ID Bernstein
    Leukemia, 2000, 14 : 474 - 475
  • [2] Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate
    Bernstein, ID
    LEUKEMIA, 2000, 14 (03) : 474 - 475
  • [3] Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195
    E Feldman
    M Kalaycio
    G Weiner
    S Frankel
    P Schulman
    L Schwartzberg
    J Jurcic
    E Velez-Garcia
    K Seiter
    D Scheinberg
    D Levitt
    N Wedel
    Leukemia, 2003, 17 : 314 - 318
  • [4] Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia
    O'Hear, Carol
    Heiber, Joshua F.
    Schubert, Ingo
    Fey, Georg
    Geiger, Terrence L.
    HAEMATOLOGICA, 2015, 100 (03) : 336 - 344
  • [5] CHARACTERIZATION OF MURINE AND HUMANIZED ANTI-CD33, GELONIN IMMUNOTOXINS REACTIVE AGAINST MYELOID LEUKEMIAS
    MCGRAW, KJ
    ROSENBLUM, MG
    CHEUNG, L
    SCHEINBERG, DA
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1994, 39 (06) : 367 - 374
  • [6] Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells
    Balaian, L
    Ball, ED
    LEUKEMIA RESEARCH, 2001, 25 (12) : 1115 - 1125
  • [7] Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858
    Eksioglu, E. A.
    Chen, X.
    Heider, K-H
    Rueter, B.
    McGraw, K. L.
    Basiorka, A. A.
    Wei, M.
    Burnette, A.
    Cheng, P.
    Lancet, J.
    Komrokji, R.
    Djeu, J.
    List, A.
    Wei, S.
    LEUKEMIA, 2017, 31 (10) : 2172 - 2180
  • [8] Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858
    E A Eksioglu
    X Chen
    K-H Heider
    B Rueter
    K L McGraw
    A A Basiorka
    M Wei
    A Burnette
    P Cheng
    J Lancet
    R Komrokji
    J Djeu
    A List
    S Wei
    Leukemia, 2017, 31 : 2172 - 2180
  • [9] Therapeutic targeting of myeloid-derived suppressor cells
    Ugel, Stefano
    Delpozzo, Federica
    Desantis, Giacomo
    Papalini, Francesca
    Simonato, Francesca
    Sonda, Nada
    Zilio, Serena
    Bronte, Vincenzo
    CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (04) : 470 - 481
  • [10] Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia
    Gibson, AD
    CLINICAL LYMPHOMA, 2002, 3 (01): : 18 - 19
12345